Protagonist Therap
PTGX136.8400.94% ( +1.280 )
Protagonist Therap (PTGX)
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targe...
- Open
- 136.690
- High
- 137.000
- Low
- 133.200
- Prev. Close
- 135.560
- Volume
- 282.38K
- Turnover
- 38.38M
- Avg Price
- 135.904
- Bid/Ask Ratio
- --
- Amplitude
- 2.80%
- 52wk High
- 143.290
- Volume Ratio
- 0.54
- Turnover Ratio
- 0.54%
Protagonist Therap Analyst Rating
View MoreForecast & Rating
Jul 22, 2026Price forecast
$133.31-2.58%
Forecast & RatingStrong buy
13analysts
- Strong buy69.23%
- Buy23.08%
- Hold7.69%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · Jul 25 at 02:06 AM
Allspring Global Investments Holdings LLC Increases Stock Position in Protagonist Therapeutics, Inc. $PTGX
- Market Beat · Jul 24 at 05:10 AM
Knott David M Jr Trims Stock Holdings in Protagonist Therapeutics, Inc. $PTGX
- Simplywall · Jul 19 at 08:10 AM
Protagonist Therapeutics (PTGX) Rises In Biotech Rally While Valuation Keeps The Debate Open
- Tip Ranks · Jul 16 at 09:05 AM
Jefferies Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)
- Simplywall · Jul 9 at 10:57 PM
Will Icotyde’s Launch and Rusfertide’s Priority Review Change Protagonist Therapeutics’ (PTGX) Narrative
- Simplywall · Jul 8 at 06:56 PM
Protagonist Therapeutics (PTGX) Could Be 66% Below Fair Value As Pipeline Progress Lifts Interest
